Hepatocellular Carcinoma

Localized
- No Prior Therapy
  - 1st Line
    - IRB #2377
      - A humanitarian device exemption use protocol of TheraSphere for treatment of unresectable Hepatocellular Carcinoma
  - Prior Therapy
    - 2nd line
      - IRB #16133
        - A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

Cholangiocarcinoma
- 1st Line
- 1st or 2nd Line

IRB #17603
- No Trials Currently Available

IRB #16033
- No Trials Currently Available

IRB #16255
- INCB 54828-202: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php